Heparin-induced thrombocytopenia: a review of concepts regarding a dangerous adverse drug reaction  by Junqueira, Daniela Rezende Garcia et al.
r e v a s s o c m e d b r a s . 2 0 1 3;5  9(2):161–166
Revista da
O
H
r
D
a
b
a
A
R
A
K
D
A
H
T
P
T
A
H
T
B
0
hASSOCIAÇÃO MÉDICA BRASILEIRA
www.ramb.org .br
riginal article
eparin-induced  thrombocytopenia:  a review  of concepts
egarding a dangerous  adverse  drug  reaction
aniela Rezende Garcia Junqueiraa,b,∗, Maria das Grac¸as Carvalhob, Edson Perinib
The University of Sydney, Sydney, Australia
Centro de Estudos do Medicamento (Cemed), Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 27 July 2012
ccepted 4 November 2012
eywords:
rug toxicity
nticoagulants
eparin
hrombocytopenia
a  b  s  t  r  a  c  t
Heparin is a natural agent with antithrombotic action, commercially available for thera-
peutic use as unfractionated heparin and low molecular weight heparin. Heparin-induced
thrombocytopenia (HIT) is a serious adverse reaction to heparin that promotes antibody-
mediated platelet activation. HIT is deﬁned as a relative reduction in platelet count of 50%
(even when the platelet count at its lowest level is above > 150 x 109/L) occurring within ﬁve
to  14 days after initiation of the therapy. Thrombocytopenia is the main feature that directs
the clinical suspicion of the reaction and the increased risk of thromboembolic complica-
tions is the most important and paradoxical consequence. The diagnosis is a delicate issue,
and  requires a combination of clinical probability and laboratory tests for the detection of
platelet activation induced by HIT antibodies. The absolute risk of HIT has been estimated
between 1% and 5% under treatment with unfractionated heparin, and less than 1% with
low molecular weight heparin. However, high-quality evidence about the risk of HIT from
randomized clinical trials is scarce. In addition, information on the frequency of HIT in
developing countries is not widely available. This review aims to provide a better under-
standing of the key features of this reaction and updated information on its frequency to
health professionals and other interested parties. Knowledge, familiarity, and access to ther-
apeutic options for the treatment of this adverse reaction are mandatory to minimize the
associated risks, improving patient safety.
© 2013 Elsevier Editora Ltda. 
Trombocitopenia  induzida  por  heparina:  revisão  de  conceitos  de  uma
importante  reac¸ão adversa  a  medicamentos
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baixo estiver acima 150 x 109/L) que pode ocorrer no período de cinco a 14 dias após o início
da  terapia com o medicamento. A trombocitopenia é a principal característica que direciona
a  suspeita clínica da reac¸ão, sendo o aumento do risco de complicac¸ões tromboembólicas a
consequência mais importante e paradoxal. O diagnóstico é uma  questão delicada e requer
a  combinac¸ão da probabilidade clínica com testes laboratoriais para detectar a ativac¸ão pla-
quetária induzida pelos anticorpos da TIH. O risco absoluto de TIH tem sido estimado entre 1
e  5% no tratamento com heparina não fracionada e inferior a 1% no uso de heparina de baixo
peso molecular. No entanto, evidências de alta qualidade provenientes de ensaios clínicos
randomizados sobre a frequência dessa reac¸ão são escassas. Além disso, informac¸ões sobre
a  frequência de TIH em países em desenvolvimento não são amplamente disponíveis. Esta
revisão teve como objetivo fornecer aos proﬁssionais de saúde e demais interessados um
melhor conhecimento sobre a TIH e as principais características dessa reac¸ão, bem como
apresentar dados atualizados sobre a frequência da mesma. Conhecimento, familiaridade e
acesso a opc¸ões terapêuticas para o tratamento dessa reac¸ão adversa são necessários para
minimizar os riscos associados, melhorando a seguranc¸a do paciente.
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Introduction
Heparin is one of the most commonly used medications world-
wide, with over one trillion units used in the United States
yearly.1 It is an anticoagulant that occurs naturally in the
organism in small amounts, and whose activity is expressed
through ligation to a plasma cofactor, the antithrombin, thus
inactivating thrombin (factor IIa) and factors Xa, IXa, and Xia.2
For medicinal purposes, the drug is extracted from animal
mucosa (swine or bovine), and used mainly in the treatment
and prophylaxis of thromboembolic disorders.
There are two types of heparin drugs available: unfrac-
tionated heparin (UFH), also called standard heparin; and
low-molecular-weight heparin (LMWH). UFH is a heteroge-
neous mixture of glycosaminoglycans with molecular weight
ranging from 3,000 to 30,000 on average. LMWH  is obtained
by fractionation or depolymerization of standard heparin
yielding fragments, with mean molecular weight ranging
from 4,500 to 5,000.2,3 Therefore, LMWH  constitutes a group
of several drugs (e.g. enoxaparin, dalteparin, nadroparin,
tinzaparin, etc.) differing in some extent in their pharma-
cokinetic properties and anticoagulant proﬁle, since they
are prepared by different methods of depolymerization.
LMWH  presents a more  predictable dose-response relation-
ship and an improved bioavailability after subcutaneous
administration due to reduced binding to plasma proteins,
macrophages, and endothelial cells, thus allowing for a ﬁxed-
dose regime.2,4
Among the possible adverse effects during treatment with
heparin, hemorrhage is the main and best-known risk, occur-
ring in 5% to 10% of exposed patients.3 Another important
adverse drug reaction faced by clinicians during treatment
with heparin is heparin-induced thrombocytopenia (HIT),
potentially the most morbid complication of heparin ther-
apy. Formerly termed white clot syndrome or HIT type II,
HIT is a type of acquired hypercoagulability syndrome caused
by an immune-mediated reaction induced by the heparin
compound, and commonly followed by venous or arterial
thrombosis.5–7 The ﬁrst report of the association of HIT with
thrombosis dates from 1958; since then, there has been a mas-
sive effort to explain this intriguing syndrome.sevier Editora Ltda. 
Purpose  of  the  review
Considering the potential consequences of a thrombotic
event, HIT is an important and life-threatening adverse drug
reaction following treatment with heparin. Therefore, this
study aimed to review the literature addressing key character-
istics of this syndrome, its frequency, and diagnostic issues,
in order to aid HIT recognition in daily clinical practice.
Pathophysiology  of  heparin-induced
thrombocytopenia
The pathophysiology of the thrombocytopenia in HIT is still
not completely understood.8 According to the elucidated
mechanism, following the administration of heparin, platelet
factor 4 (PF4), a small peptide stored in platelet -granules, is
released in blood circulation due to a transient and unspeciﬁc
platelet aggregation induced by direct interaction of platelets
with heparin.9 Subsequently, heparin binds to PF4 due to
charge differences, thus resulting in a macromolecular com-
plex (PF4/heparin). The formation of this complex induces a
conformational change in the molecules, resulting in the for-
mation of several neo-epitopes.2,10,11 An immune response
against these antigenic epitopes results in the production of
IgG, IgM, and IgA antibodies.
The clinical importance of IgA and IgM antibodies remains
uncertain, as they appear unable to cause platelet activa-
tion in the presence of heparin,12,13 although in a few HIT
cases (< 10%), only IgA or IgM antibodies to PF4/heparin are
detectable.11 The IgG antibodies react with the PF4/heparin
complex, forming an immunocomplex of PF4/heparin/IgG
antibodies (HIT antibodies), which has the ability to bind to
platelets’ surfaces through their FcyRIIa receptor, inducing
platelet activation and aggregation.14,15 The intensive platelet
activation induced by HIT antibodies increases thrombin gen-
eration, thus determining a hypercoagulability state.16,17
Este é um artigo Open Access sob a licença de CC BY-NC-NDObservational data regarding the prevalence of HIT in the
setting of local or systemic inﬂammation have also raised
the possibility that additional cell types are involved in
the pathogenesis of thrombosis, including leukocyte-platelet
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ggregates and monocytes.8,18 HIT antibodies can bind to
onocytes, prompting their degranulation and the release of
everal procoagulant and inﬂammatory substances.19 More-
ver, there is evidence that activated monocytes express tissue
actor on their surface, which reinforces the activation of
he coagulation pathway.6 The activated coagulation system
lso determines the release of vesicular platelet-membrane
platelet microparticles), which contains substances (GPIb,
PIIb, and GPIIIa, P-selectin, and thrombospondin) capable
f increasing thrombin generation in vivo.10,20,21 In addition,
ndothelial damage certainly plays a role in HIT pathogen-
sis, since it can be caused by immunoglobulins, cytokines
eleased by activated leukocytes, microparticles from acti-
ated platelets, adhesion molecules from both activated
latelets and leukocytes, as well as by mechanical disrup-
ion due to surgical processes or pathological processes such
s atherosclerosis.6 Recently, in the setting of cardiothoracic
atients, one study reported that HIT patients have posi-
ive antibodies to Adamts-13 and a reduced concentration
f Adamts-13, which could be a complicating factor in HIT
athogenesis.22 Considering that patients needing antithrom-
otic therapy with heparin may be bedridden at least to some
xtent, the procoagulant state, together with vascular injury
nd stasis, may be a central mechanism of the venous and
rterial thrombosis associated with the development of HIT.
It has been shown that there is dissociation between
he development of HIT antibodies and the risk of HIT
ccurrence.23 Therefore, not all patients who form HIT anti-
odies will develop thrombocytopenia or other sequelae of
IT.7,24 The reticuloendothelial system may clear platelets
oated with antibodies from circulation, thus preventing the
linical manifestation of HIT in most patients.19 However, the
eason why some patients develop antibodies with the ability
o activate platelets (functional antibodies) and others do not
s currently unknown.25
eﬁnitions  and  fundamental  characteristics
f heparin-induced  thrombocytopenia
IT is deﬁned as a relative reduction in platelet count of
0% (even when the count of platelets at its lowest level is
bove > 150 x 109/L) occurring within ﬁve to 14 days after
tarting heparin therapy.26 Remarkably, HIT differs from a
on-immune heparin-associated thrombocytopenia (HAT),
hich is secondary to a direct interaction of heparin with
latelets and resolves spontaneously.10
The time pattern of HIT may be difﬁcult to recognize
n the postoperative setting since platelet counts commonly
ecrease after a surgical procedure.26 Therefore, in postop-
rative patients, thrombocytopenia in HIT may be deﬁned
s a drop in platelet counts of 50% or more  from the maxi-
um number of platelets, occurring after surgery and within
he predeﬁned time frame.27 Noticeably, patients recently
xposed to heparin may have circulating antibodies, and then
hey can develop rapid-onset HIT within 24 hours after a new
13eparin administration. Delayed-onset HIT, when the syn-
rome occurs months after the discontinuation of heparin,
as also been described.28,29 Delayed-onset HIT is typically
ecognised because of a thrombotic event; the possibility of an1 3;5  9(2):161–166 163
unsuccessful long-term anticoagulant therapy is a challenge
to the diagnosis of the syndrome.12
Clinical suspicion of this adverse drug reaction mainly
occurs because of thrombocytopenia, which is the central fea-
ture of the syndrome. However, the clinical suspicion must
be conﬁrmed by the demonstration of antibodies with ability
to induce platelet activation.26 Thrombotic events may also
prompt a suspicion of HIT, since these complications can occur
in an unpredictable manner throughout the use of the drug,
and even before thrombocytopenia status is reached.7,30
Diagnosis  and  treatment  of  heparin-induced
thrombocytopenia
The diagnosis of HIT is a challenging issue. It requires the
combination of clinical likelihood and laboratory tests to
detect platelet activation induced by HIT antibodies.31,32 Some
assays, known as functional assays, are able to demonstrate
the presence of clinically relevant antibodies.33 These assays
are the C-serotonin released assay (SRA)14 and the heparin-
induced platelet activation assay (HIPA), which also present
the most favourable sensitivity/speciﬁcity trade-off.33,34
The platelet aggregation assay has also been used, but lacks
adequate sensitivity and is not generally recommended.35
Another available procedure is detection of HIT antibodies in
the patient’s sera through immunoassays. There are a number
of commercial enzyme-linked immunoassays (ELISA) avail-
able to diagnose HIT. They are able to detect pathogenic and
non-pathogenic antibodies, and commonly lead to a high
rate of false-positives.33 However, despite their low speciﬁcity,
these assays represent an ideal test to rule out HIT; their com-
bination with a functional assay can be a valuable procedure
to screen negative cases. Thus, functional assays should be
reserved to just a small numbers of cases.
A clinical scoring system aiming to improve the
clinical diagnosis of HIT has been developed.32 Using
four clinical features of HIT (magnitude of thrombocytopenia,
timing of thrombocytopenia regarding heparin exposure,
occurrence of thrombosis or other sequelae, and absence of
other explanations for the thrombocytopenia), the 4Ts sco-
ring system is a risk assessment tool that classiﬁes patients
within low, moderate, and high probabilities for HIT. Several
studies have investigated the usefulness of combining the
4Ts scoring system and laboratory testing in the diagnosis of
HIT.36,37 However, this method may lack satisfactory ability
to identify the probability of HIT in order to be widely used in
clinical practice.38,39
Considering the role of thrombin generation in HIT patho-
genesis, all sources of heparin should be suspended when
the reaction occurs. In case of a strong suspicion, the results
of the assays should not even be waited for.40 However, the
cost-beneﬁt of introducing a treatment with an alternative
anticoagulant must be considered in the clinical decision-
process, due to signiﬁcant risk of bleeding.34 There is a
rationale for the use of direct thrombin inhibitors (argatroban,
lepirudin, or bivalirudin) and of an agent anti-factor Xa (fon-
daparinux) that inhibits thrombin generation to treat HIT.
Treatment must continue until platelet count becomes nor-
mal, and asymptomatic thrombosis should be investigated.
 a s . 2
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In cases of HIT complicated by thromboembolic events, ther-
apy with alternative anticoagulants must be carefully followed
by therapy with warfarin for two or three months.35 An
evidence-based guideline regarding the management of HIT
is available.19
Some procedures should be avoided in the management
of HIT. LMWH  is not a therapeutic option, since it cross-
reacts with circulating HIT antibodies.31,40 Oral anticoagulant
drugs must also not be used because they reduce protein C
and S levels, thus contributing to an increase in thrombin
generation and resulting in a higher risk of thromboem-
bolic complications.32 Indeed, venous gangrene has developed
in patients treated for HIT with oral anticoagulants. There-
fore, warfarin therapy may be carefully started only after the
platelet count becomes normal. Platelet transfusion should
not be performed, as it might induce or exacerbate throm-
boembolic complications.40
Frequency  of  heparin-induced
thrombocytopenia
HIT may develop following any mode of heparin
administration,10,34 including parenteral infusions,28 subcu-
taneous therapy,41 and even due to low-grade exposures such
as heparin line ﬂushes or following the insertion of heparin-
bonded pulmonary artery catheters.42 The development of
HIT is inﬂuenced by the type of heparin used (UFH or LMWH)
and the type of heparin-exposed patient population.34 Also,
the incidence of HIT appears to be higher with the use of
bovine heparin when compared with swine heparin. However,
data regarding accurate values of the incidence of HIT are
conﬂicting.34 Overall, it has been generally accepted that the
absolute risk of HIT during treatment with UFH is between
1% to 5%, and between 0.1% to 1% with LMWH.19,26,43 The
association of HIT with the type of heparin may be justiﬁed
by the higher molecular weight and degree of sulphation of
the UFH, which determine a higher probability to induce the
formation of HIT antibodies when compared to the LMWH.
The highest risk population comprises postoperative
patients receiving UFH (estimated incidence between 1% to
5%).34 Postoperative patients receiving LMWH  show a lower
risk of HIT (estimated incidence between 0.1% to 1%), together
with medical and obstetrical patients exposed to UFH.41
In other settings, such as medical and obstetrical patients
exposed only to LMWH  or receiving catheter ﬂushes with UFH,
HIT is described as a rare event, with an incidence < 0.1%,34
although higher frequencies have been observed.44 Speciﬁc
characteristics of patients submitted to certain surgeries were
also shown to inﬂuence the risk proﬁle of HIT;18,23 however,
most studies have enrolled patients after orthopedic surgery.
Recent investigations presented weak evidence suppor-
ting the generally accepted incidence of HIT. Although a
lower incidence of HIT in postoperative patients under throm-
boprophylaxis with LMWH  when compared with UFH was
shown, randomized clinical trials that include HIT as an
45outcome are scarce. Of note, in a recently published sys-
tematic review, the absolute risk (incidence) of HIT in patients
subjected to major surgeries was found to be similar for
both types of heparins (incidence > 1% and < 10%) .45 These
1 0 1 3;5  9(2):161–166
ﬁndings are preliminary, but may possibly impact clinical rec-
ommendations regarding platelet count monitoring during
thromboprophylaxis with heparin.
Special concern should be addressed regarding the fre-
quency of HIT in Brazil. To the authors’ knowledge, there is no
available information about the incidence of HIT in Brazil or
in Latin America, and little information is available about the
frequency of HIT in other developing countries. This is a con-
cern, since the speciﬁcities in the population composition and
its genetics can clearly inﬂuence the effects of drugs.46 Most
importantly, bovine heparin has shown a higher potential to
induce HIT when compared with swine heparin. While most
countries do not produce this kind of heparin anymore, 40%
of the manufactured products containing heparin in Brazil are
derived from a bovine source.47 Therefore, there is a need for
an improvement of knowledge and awareness regarding the
occurrence of this adverse drug reaction in the clinical practice
of Brazil. The poorly understood picture of HIT in this country
may contribute to a delayed recognition of the syndrome, thus
negatively impacting morbidity and mortality of patients.
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